Pamiparib in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with newly diagnosed (ND) or recurrent/refractory (R/R) glioblastoma (GBM); phase 1b/2 study update

Anna Piotrowski1, Vinay Puduvalli2, Patrick Y. Wen3, Howard Colman4, Jian Campian5, Michael Pearlman6, Nicholas Butowski7, Timothy Cloughesy8, James Battiste9, Jon Glass10, David Schiff11, Martin van den Bent12, Tobias Walbert13, Manmeet Ahluwalia14, Michael Badruddoja15, Amandeep Kalra16, Robert Pelham17, Kathy Zhang17, Katie Wood17, Michael Weller18, Kent Shih19

1Memorial Sloan Kettering Cancer Center, New York, NY; 2The Ohio State University, Columbus, OH; 3Dana Farber Cancer Institute, Boston, MA; 4Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT; 5Washington University, St. Louis, MO; 6Sarah Cannon Research Institute at Health One, Denver, CO; 7University of California at San Francisco, San Francisco, CA; 8University of California at Los Angeles, Neuro-Oncology, Los Angeles, CA; 9Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK; 10Thomas Jefferson University, Philadelphia, PA; 11University of Virginia Health Systems, Emily Couric Clinical Cancer Center, Charlottesville, VA; 12Erasmus University Medical Center, Rotterdam, Netherlands; 13Henry Ford Hospital, Detroit, MI; 14Cleveland Clinic, Cleveland, OH; 15Center for Neurosciences, Tucson, AZ; 16Health Midwest Ventures Group, LLC, Kansas City, MO; 17BeiGene USA, Inc., San Mateo, CA; 18UniversitätsSpital Zürich - Klinik für Neurologie, Zürich, Switzerland; 19Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN

Pamiparib, an investigational, oral PARP 1/2 inhibitor, demonstrated preclinical brain penetration and synergistic cytotoxicity with TMZ. We report updated safety and antitumor data for pamiparib plus RT and/or TMZ in ND-GBM or R/R-GBM (SNO 2019, ACTR-39). This dose-escalation/expansion study includes three arms: A, pamiparib (2, 4, or 6 weeks) plus RT (6-7 weeks) in ND-GBM with unmethylated MGMT promoter ( unmethylated-GBM); B, pamiparib (6 weeks) plus RT and increasing TMZ doses in Weeks 1 and 5 of RT in unmethylated ND-GBM; and C, pamiparib plus increasing TMZ doses in methylated/unmethylated R/R-GBM. Most patients in Arms A (expansion) and B received maintenance pamiparib plus TMZ after post-RT rest period at Arm C expansion. As of April 10, 2020, enrollment was complete (N=116; A, n=60; B, n=9; C, n=47). Median study follow-up was 11.3 mo (A/B) and 7.1 mo (C). Common grade ≥3 AEs were anemia (10%) in Arm A; decreased neutrophil and white blood cell count (each 22%) in B; anemia, fatigue, and decreased lymphocyte count (each 11%) in C. Brain edema (A) and pneumonia (C) (n=1 each) were fatal treatment-unrelated AEs. In ND-GBM, modified disease control rate (DCR following post-RT rest period) was 69.8% (95% CI, 55.7-81.7) overall, 68.8% (50.0-83.9) in A, and 80.0% (28.4-99.5) in B. Median duration of response was 5.1 mo (overall), 3.8 mo (A), and NE (B). In Arms A/B, median progression-free survival (PFS) and median overall survival (OS) were 4.4 mo and 12.7 mo, respectively; 12-mo OS rate, 54% (95% CI, 40-66). In R/R-GBM (Arm C), confirmed ORR was 9.1% (95% CI, 2.5-21.7); median PFS and OS were 1.9 mo and 7.3 mo, respectively; 6-mo PFS rate, 19% (95% CI, 9-32). These results
showed a manageable safety profile for pamiparib +/- RT +/- TMZ; response and survival results support further evaluation of these combinations in GBM.